Please use this identifier to cite or link to this item:
Title: Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy
Author: Zhang, Xuanye
Tian, Dan
Chen, Yue
Chen, Chen
He, Li-Na
Zhou, Yixin
Li, Haifeng
Lin, Zuan
Chen, Tao
Wang, Yuhong
Russo, Alessandro
Nadal, Ernest
Passiglia, Francesco
Soo, Ross Andrew
Watanabe, Satoshi
Moran, Teresa
Oh, In-Jae
Fu, Sha
Hong, Shaodong
Zhang, Li
Keywords: Càncer de pulmó
Virus de l'hepatitis B
Lung cancer
Hepatitis B virus
Issue Date: 1-Jul-2021
Publisher: AME Publishing Company
Abstract: Background: The aim of this study was to evaluate the safety and survival outcomes of anti-programmed cell death (PD)-1/programmed cell death-ligand 1 (PD-L1) monotherapy in patients with advanced nonsmall cell lung cancer (NSCLC) and different hepatitis B virus (HBV) infection status. Methods: Patients with advanced NSCLC and both chronic and/or resolved HBV infection who were treated with anti-PD-(L)1 monotherapy were retrospectively enrolled. The primary endpoint was the safety of PD-1/PD-L1 monotherapy, while the secondary endpoints included the survival outcomes. Results: Of the 62 eligible patients, 10 (16.1%) were hepatitis B surface antigen (HBsAg) positive [chronic hepatitis B (CHB) infection] and 52 (83.9%) were HBsAg negative and HBcAb positive [resolved hepatitis B (RHB) infection]; 42 (67.7%) patients had at least 1 treatment-related adverse event (AE), with 4 patients (6.5%) developing grade 3 AEs and 6 (9.7%) developing hepatic AEs. One CHB patient experienced HBV reactivation during anti-PD-1 immunotherapy due to the interruption of antiviral prophylaxis. The objective response rate and durable clinical benefit (DCB) rate were 17.7% and 29.0%, respectively. Median overall survival (OS) and progression-free survival (PFS) were 23.6 months [95% confidence interval (CI): 14.432.8] and 2.1 months (95% CI: 1.2-3.0), respectively. The DCB rate was significantly higher in the CHB group than in the RHB group (60% vs. 23.1%; P=0.048). Patients with CHB experienced a longer PFS (8.3 vs. 2.0 months; P=0.103) and OS (35.0 vs. 18.2 months, P=0.119) than did RHB patients. Conclusions: Anti-PD-(L)1 monotherapy was safe and effective in patients with NSCLC and HBV infection. This population should not be excluded from receiving immunotherapy in routine clinical practice or within clinical trials if HBV biomarkers are monitored and antiviral prophylaxis is properly used.
Note: Reproducció del document publicat a:
It is part of: Translational Lung Cancer Research, 2021, vol. 10, num. 7, p. 3191-3202
Related resource:
ISSN: 2226-4477
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Association of hepatitis B virus infection status with outcomes of.pdf843.64 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons